Cumberland Pharmaceuticals Inc. (CPIX) Financial Statements (2025 and earlier)

Company Profile

Business Address 2525 WEST END AVENUE
NASHVILLE,, TN 37203
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments17,96418,32219,75827,04124,75428,213
Cash and cash equivalent17,96418,32219,75827,04124,75428,213
Receivables11,7019,75813,1646,87712,3789,781
Inventory, net of allowances, customer advances and progress billings4,0004,6099,8648,43010,6389,412
Inventory4,0004,6099,8648,43010,6389,412
Deferred costs      
Other undisclosed current assets2,7873,0253,0853,3402,2002,757
Total current assets:36,45235,71445,87045,68849,97050,163
Noncurrent Assets
Inventory, Noncurrent11,00512,8057,5279,049  
Operating lease, right-of-use asset6,1776,6745,2181,0242,028 
Property, plant and equipment277368284443574748
Intangible assets, net (including goodwill)18,88723,52231,50524,83629,00031,802
Goodwill914914914882882882
Intangible assets, net (excluding goodwill)17,97322,60830,59123,95428,11830,920
Deferred costs     2,9003,100
Other noncurrent assets2,7842,6932,5213,4203,2343,299
Deferred tax assets, net22
Other undisclosed noncurrent assets     8,75715,416
Total noncurrent assets:39,13146,06247,05538,77246,49454,386
TOTAL ASSETS:75,58381,77692,92584,46096,463104,549
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities13,91414,03828,40718,30924,65123,230
Accounts payable13,91414,03810,8199,64113,39611,912
Accrued liabilities   17,5888,66811,25411,317
Debt 5,100     
Other liabilities12,25113,597    
Other undisclosed current liabilities3573481739701,017920
Total current liabilities:31,62227,98228,58019,27925,66724,150
Noncurrent Liabilities
Long-term debt and lease obligation10,17612,78416,20015,09016,06018,500
Long-term debt, excluding current maturities10,17612,78416,20015,00015,00018,500
Liabilities, other than long-term debt11,24011,75012,1717,4897,8638,737
Other liabilities6,3006,4547,5857,4897,8638,737
Operating lease, liability4,9405,2964,586901,060 
Other undisclosed noncurrent liabilities      2,076
Total noncurrent liabilities:21,41624,53428,37122,57923,92229,314
Total liabilities:53,03752,51656,95141,85849,59053,464
Equity
Equity, attributable to parent, including:22,85329,60336,26642,81446,99151,123
Retained earnings (accumulated deficit)(23,968)(17,488)(11,209)(5,639)(2,131)1,208
Other undisclosed equity, attributable to parent46,82147,09247,47548,45349,12249,914
Equity, attributable to noncontrolling interest(308)(344)(292)(212)(117)(38)
Total equity:22,54629,26035,97442,60246,87351,085
TOTAL LIABILITIES AND EQUITY:75,58381,77692,92584,46096,463104,549

Income Statement (P&L) ($ in thousands)

3/31/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues37,86839,55342,01135,98537,44147,534
Cost of revenue
(Cost of Product and Service Sold)
(6,586)(6,067)(9,119)(8,811)(8,653)(8,752)
Gross profit:31,28233,48632,89227,17428,78838,782
Operating expenses(37,714)(43,041)(38,597)(34,851)(35,170)(42,405)
Operating loss:(6,432)(9,555)(5,705)(7,677)(6,382)(3,623)
Nonoperating income
(Investment Income, Nonoperating)
3342877102675243
Interest and debt expense  (668)(586)(98)(264)(246)
Loss from continuing operations before equity method investments, income taxes:(6,098)(9,936)(5,581)(7,749)(6,570)(3,626)
Other undisclosed income (loss) from continuing operations before income taxes(368)3,651 2,187  
Loss from continuing operations before income taxes:(6,466)(6,285)(5,581)(5,562)(6,570)(3,626)
Income tax expense (benefit)23(46)(69)(35)(56)79
Loss from continuing operations:(6,444)(6,331)(5,650)(5,597)(6,626)(3,547)
Loss before gain (loss) on sale of properties:(3,603)(3,419)(3,547)
Income from discontinued operations    1,9943,207 
Net loss:(6,444)(6,331)(5,650)(3,603)(3,419)(3,547)
Net income (loss) attributable to noncontrolling interest(36)518095799
Net loss available to common stockholders, diluted:(6,480)(6,279)(5,570)(3,508)(3,339)(3,538)

Comprehensive Income ($ in thousands)

3/31/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(6,444)(6,331)(5,650)(3,603)(3,419)(3,547)
Other undisclosed comprehensive income      9
Comprehensive loss:(6,444)(6,331)(5,650)(3,603)(3,419)(3,538)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest(36)5180957918
Other undisclosed comprehensive loss, net of tax, attributable to parent      (26)
Comprehensive loss, net of tax, attributable to parent:(6,480)(6,279)(5,570)(3,508)(3,339)(3,547)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: